TWI850657B - 結晶形式 - Google Patents

結晶形式 Download PDF

Info

Publication number
TWI850657B
TWI850657B TW111117204A TW111117204A TWI850657B TW I850657 B TWI850657 B TW I850657B TW 111117204 A TW111117204 A TW 111117204A TW 111117204 A TW111117204 A TW 111117204A TW I850657 B TWI850657 B TW I850657B
Authority
TW
Taiwan
Prior art keywords
crystalline form
compound
formula
adduct
pharmaceutical composition
Prior art date
Application number
TW111117204A
Other languages
English (en)
Chinese (zh)
Other versions
TW202342460A (zh
Inventor
薩拉薩爾 約蘇 揚 巴拉
阿雷瓦洛 埃內克 阿爾達瓦
伊格萊西亞斯 塔瑪拉 貝洛
布埃拉 勞雷亞諾 西蒙
Original Assignee
西班牙商奎馬特裏克斯有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 西班牙商奎馬特裏克斯有限公司 filed Critical 西班牙商奎馬特裏克斯有限公司
Publication of TW202342460A publication Critical patent/TW202342460A/zh
Application granted granted Critical
Publication of TWI850657B publication Critical patent/TWI850657B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01098—Histone deacetylase (3.5.1.98), i.e. sirtuin deacetylase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Peptides Or Proteins (AREA)
TW111117204A 2022-04-19 2022-05-06 結晶形式 TWI850657B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210409814.5A CN114634489B (zh) 2022-04-19 2022-04-19 结晶形式
CN202210409814.5 2022-04-19

Publications (2)

Publication Number Publication Date
TW202342460A TW202342460A (zh) 2023-11-01
TWI850657B true TWI850657B (zh) 2024-08-01

Family

ID=81940491

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111117204A TWI850657B (zh) 2022-04-19 2022-05-06 結晶形式

Country Status (6)

Country Link
US (1) US20260070895A1 (https=)
EP (1) EP4511124A1 (https=)
JP (1) JP2025514066A (https=)
CN (1) CN114634489B (https=)
TW (1) TWI850657B (https=)
WO (1) WO2023202787A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011039353A1 (en) * 2009-10-02 2011-04-07 Ikerchem, S.L. New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
AR053046A1 (es) * 2005-04-07 2007-04-18 Teijin Pharma Ltd Cristal de derivado de aminonopirrolidina y metodo de produccion del mismo
EP3327007B1 (en) * 2015-07-24 2020-06-03 Shenzhen Zhenxing Medical Technology Co., Ltd. Orbit azine-fumarate, hydrate, crystal form and preparation method therefor
CN107759600A (zh) * 2016-06-16 2018-03-06 正大天晴药业集团股份有限公司 作为jak抑制剂的吡咯并嘧啶化合物的结晶
EP3318256A1 (en) 2016-11-08 2018-05-09 Quimatryx, S.L Compounds for the treatment of autoimmune diseases
AU2020259100B2 (en) * 2019-04-17 2024-12-12 Fundación Kertor 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011039353A1 (en) * 2009-10-02 2011-04-07 Ikerchem, S.L. New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers

Also Published As

Publication number Publication date
EP4511124A1 (en) 2025-02-26
CN114634489A (zh) 2022-06-17
US20260070895A1 (en) 2026-03-12
CN114634489B (zh) 2023-07-04
JP2025514066A (ja) 2025-05-02
TW202342460A (zh) 2023-11-01
WO2023202787A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
US10519176B2 (en) Crystalline forms
CN105848718B (zh) Aramchol盐
TW200403210A (en) Benzamide derivatives
KR102791742B1 (ko) (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산의 합성을 위한 공정
EA007613B1 (ru) Бензолсульфонатная соль (2s,4s)-1-циано-4-фтор-1-[(2-гидрокси-1,1-диметил)этиламино]ацетилпирролидина
JP2018531288A6 (ja) ピリミジン組成物、超高純度組成物およびその塩、それを作成する方法、ならびにヒスタミンｈ４受容体（ｈ４）によって媒介される疾患および状態を治療するためにそれを用いる方法
CZ78896A3 (en) Crystalline anhydrous micophenolate (of mofetil) and intravenous preparation containing thereof
JP2018531288A (ja) ピリミジン組成物、超高純度組成物およびその塩、それを作成する方法、ならびにヒスタミンｈ４受容体（ｈ４）によって媒介される疾患および状態を治療するためにそれを用いる方法
CN115385894A (zh) 与吡啶酰基哌啶5-ht1f激动剂相关的组合物和方法
CN105263924B (zh) Cxcr7受体调节剂
CN106279121A (zh) 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
TW202444341A (zh) 萘胺類粒線體自噬誘導劑的固體形式、其製備方法、藥物組合物和用途
TWI850657B (zh) 結晶形式
JPH10506410A (ja) 抗腫瘍剤及び抗ウイルス剤としてのビス−（２−ハロエチル）アミノフェニル置換ジスタマイシン誘導体
HK40066780A (zh) 结晶形式
CN111372579A (zh) 取代的苯基磺酰基苯基三唑硫酮和其用途
HK40066780B (en) Crystalline forms
SK152095A3 (en) Crystalline (+) l-hydrogentartrate, preparation method thereof, pharmaceutical composition containing its and its use
CN115141136A (zh) 特考韦瑞药的共晶及其制备方法
WO2025189654A1 (zh) 喹啉酮类药物共晶及其制备方法、药物组合物和应用
HK40116055A (zh) 结构化α-2A肾上腺素受体激动剂的异苯并二氢吡喃-咪唑的新硫酸盐形式
CN121930131A (zh) 化合物及其在治疗nmdar相关疾病中的用途
PL185709B1 (pl) Nowy monohydrat polimorfu II 6-N-(L-Ala-L-Ala)-trowafloksacyny i środek farmaceutyczny
JPH06505699A (ja) 精神活性薬及び治療
CN115252583A (zh) 复方盐酸替利定缓释制剂及其制备方法